Servier hit by bone drug safety issues as Mediator continues to make waves
This article was originally published in Scrip
Executive Summary
The French company Servier, already staggering under the weight of the Mediator affair, is again under fire, this time over the safety profile of its osteoporosis drug, Protelos (strontium ranelate). A French committee is examining the pharmacovigilance data on the product to see whether its risk-benefit profile needs to change, and Servier's pharmacovigilance systems are also under the spotlight.